Despite macroeconomic concerns, currency headwinds and related cost inflation, Boston Scientific Corporation (BSX) is seeing strength across target markets. The company is demonstrating growth backed by its category leadership strategy, which is fueled by innovation, clinical evidence generation and the strong execution power of the global team. The market is also upbeat about the recently closed acquisition of Axonics, which is expected to show high synergy benefits within the company’s Urology business.Bo ...